-
1
-
-
84873956600
-
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
-
Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
-
(2013)
Am J Respir Crit Care Med
, vol.187
, pp. 347-365
-
-
Vestbo, J.1
Hurd, S.S.2
Agusti, A.G.3
-
2
-
-
84918801105
-
Inhaled steroids in COPD: When should they be used?
-
Agusti A, Fabbri LM. Inhaled steroids in COPD: When should they be used? Lancet Respir Med 2014; 2: 869-871.
-
(2014)
Lancet Respir Med
, vol.2
, pp. 869-871
-
-
Agusti, A.1
Fabbri, L.M.2
-
3
-
-
84885766455
-
Inhaled corticosteroids in COPD and the risk of serious pneumonia
-
Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
-
(2013)
Thorax
, vol.68
, pp. 1029-1036
-
-
Suissa, S.1
Patenaude, V.2
Lapi, F.3
-
4
-
-
84887503251
-
The yin and the yang of immunosuppression with inhaled corticosteroids
-
Sabroe I, Postma D, Heijink I, et al. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 2013: 1085-1087.
-
(2013)
Thorax
, pp. 1085-1087
-
-
Sabroe, I.1
Postma, D.2
Heijink, I.3
-
5
-
-
84944880515
-
The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK
-
Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10: 2207-2217.
-
(2015)
Int J Chron Obstruct Pulmon Dis
, vol.10
, pp. 2207-2217
-
-
Brusselle, G.1
Price, D.2
Gruffydd-Jones, K.3
-
6
-
-
84907779764
-
Withdrawal of inhaled glucocorticoids and exacerbations of COPD
-
Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294.
-
(2014)
N Engl J Med
, vol.371
, pp. 1285-1294
-
-
Magnussen, H.1
Disse, B.2
Rodriguez-Roisin, R.3
-
7
-
-
84928384173
-
New combination bronchodilators for chronic obstructive pulmonary disease: Current evidence and future perspectives
-
Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol 2015; 79: 695-708.
-
(2015)
Br J Clin Pharmacol
, vol.79
, pp. 695-708
-
-
Singh, D.1
-
8
-
-
0031731419
-
Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis
-
Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-1517.
-
(1998)
Am J Respir Crit Care Med
, vol.158
, pp. 1511-1517
-
-
Pizzichini, E.1
Pizzichini, M.M.2
Gibson, P.3
-
9
-
-
0034727453
-
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial
-
Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2000; 356: 1480-1485.
-
(2000)
Lancet
, vol.356
, pp. 1480-1485
-
-
Brightling, C.E.1
Monteiro, W.2
Ward, R.3
-
10
-
-
20144382091
-
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease
-
Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198.
-
(2005)
Thorax
, vol.60
, pp. 193-198
-
-
Brightling, C.E.1
McKenna, S.2
Hargadon, B.3
-
11
-
-
34248206610
-
Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial
-
Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007; 29: 906-913.
-
(2007)
Eur Respir J
, vol.29
, pp. 906-913
-
-
Siva, R.1
Green, R.H.2
Brightling, C.E.3
-
12
-
-
84879411561
-
Multidimensional assessment and tailored interventions for COPD: Respiratory utopia or common sense?
-
McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68: 691-694.
-
(2013)
Thorax
, vol.68
, pp. 691-694
-
-
McDonald, V.M.1
Higgins, I.2
Wood, L.G.3
-
13
-
-
33646565124
-
Outcomes and markers in the assessment of chronic obstructive pulmonary disease
-
Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832.
-
(2006)
Eur Respir J
, vol.27
, pp. 822-832
-
-
Jones, P.W.1
Agusti, A.G.2
-
14
-
-
0030811544
-
The use of induced sputum to investigate airway inflammation
-
Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498-501.
-
(1997)
Thorax
, vol.52
, pp. 498-501
-
-
Pavord, I.D.1
Pizzichini, M.M.2
Pizzichini, E.3
-
15
-
-
80052936263
-
Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers
-
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 662-671
-
-
Bafadhel, M.1
McKenna, S.2
Terry, S.3
-
16
-
-
84916235780
-
Eosinophilic inflammation in COPD: Prevalence and clinical characteristics
-
Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697-1700.
-
(2014)
Eur Respir J
, vol.44
, pp. 1697-1700
-
-
Singh, D.1
Kolsum, U.2
Brightling, C.E.3
-
17
-
-
84865145614
-
Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial
-
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
-
(2012)
Lancet
, vol.380
, pp. 651-659
-
-
Pavord, I.D.1
Korn, S.2
Howarth, P.3
-
18
-
-
0014106861
-
The total eosinophil count in a non-atopic population
-
Felarca A, Lowell F. The total eosinophil count in a non-atopic population. J Allergy 1967; 40: 4.
-
(1967)
J Allergy
, vol.40
, pp. 4
-
-
Felarca, A.1
Lowell, F.2
-
19
-
-
84969872387
-
Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD
-
Schleich F, Corhay J-L, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J 2016; 47: 1562-1564.
-
(2016)
Eur Respir J
, vol.47
, pp. 1562-1564
-
-
Schleich, F.1
Corhay, J.-L.2
Louis, R.3
-
20
-
-
84884905728
-
Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects
-
Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132: 821-827.
-
(2013)
J Allergy Clin Immunol
, vol.132
, pp. 821-827
-
-
Malinovschi, A.1
Fonseca, J.A.2
Jacinto, T.3
-
21
-
-
84930866341
-
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials
-
Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
-
(2015)
Lancet Respir Med
, vol.3
, pp. 435-442
-
-
Pascoe, S.1
Locantore, N.2
Dransfield, M.T.3
-
22
-
-
84939433292
-
Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease
-
Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192: 523-525.
-
(2015)
Am J Respir Crit Care Med
, vol.192
, pp. 523-525
-
-
Siddiqui, S.H.1
Guasconi, A.2
Vestbo, J.3
-
23
-
-
84958985825
-
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
-
Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016; 71: 118-125.
-
(2016)
Thorax
, vol.71
, pp. 118-125
-
-
Pavord, I.D.1
Lettis, S.2
Locantore, N.3
-
24
-
-
84930754960
-
A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ?2% and >2% blood eosinophils
-
Marks-Konczalik J, Costa M, Robertson J, et al. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ?2% and >2% blood eosinophils. Respir Med 2015; 109: 860-869.
-
(2015)
Respir Med
, vol.109
, pp. 860-869
-
-
Marks-Konczalik, J.1
Costa, M.2
Robertson, J.3
-
25
-
-
84907216438
-
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
-
Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis. Eur Respir J 2014: 789-791.
-
(2014)
Eur Respir J
, pp. 789-791
-
-
Bafadhel, M.1
Davies, L.2
Calverley, P.M.3
-
26
-
-
84863447204
-
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial
-
Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
-
(2012)
Am J Respir Crit Care Med
, vol.186
, pp. 48-55
-
-
Bafadhel, M.1
McKenna, S.2
Terry, S.3
-
27
-
-
0034007758
-
Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample
-
Hospers JJ, Schouten JP, Weiss ST, et al. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology 2000; 11: 261-268.
-
(2000)
Epidemiology
, vol.11
, pp. 261-268
-
-
Hospers, J.J.1
Schouten, J.P.2
Weiss, S.T.3
-
28
-
-
0033431650
-
Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample
-
Hospers JJ, Schouten JP, Weiss ST, et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 1999; 160: 1869-1874.
-
(1999)
Am J Respir Crit Care Med
, vol.160
, pp. 1869-1874
-
-
Hospers, J.J.1
Schouten, J.P.2
Weiss, S.T.3
-
29
-
-
33847172367
-
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
-
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
-
(2007)
N Engl J Med
, vol.356
, pp. 775-789
-
-
Calverley, P.M.1
Anderson, J.A.2
Celli, B.3
-
30
-
-
48949103222
-
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study
-
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 332-338
-
-
Celli, B.R.1
Thomas, N.E.2
Anderson, J.A.3
-
31
-
-
84969750034
-
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD
-
Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016; 47: 1374-1382.
-
(2016)
Eur Respir J
, vol.47
, pp. 1374-1382
-
-
Barnes, N.C.1
Sharma, R.2
Lettis, S.3
-
32
-
-
0034643610
-
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
-
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320: 1297-1303.
-
(2000)
BMJ
, vol.320
, pp. 1297-1303
-
-
Burge, P.S.1
Calverley, P.M.2
Jones, P.W.3
-
33
-
-
84936762052
-
Lung-function trajectories leading to chronic obstructive pulmonary disease
-
Lange P, Celli B, Agusti A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111-122.
-
(2015)
N Engl J Med
, vol.373
, pp. 111-122
-
-
Lange, P.1
Celli, B.2
Agusti, A.3
-
34
-
-
84896765479
-
Year in review 2013: Paediatric and adult clinical studies
-
Bush A, Pavord I. Year in review 2013: paediatric and adult clinical studies. Thorax 2014; 69: 309-311.
-
(2014)
Thorax
, vol.69
, pp. 309-311
-
-
Bush, A.1
Pavord, I.2
-
35
-
-
84958073595
-
Treatable traits: Toward precision medicine of chronic airway diseases
-
Agusti A, Bel E, Thomas M, et al. Treatable traits: Toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
-
(2016)
Eur Respir J
, vol.47
, pp. 410-419
-
-
Agusti, A.1
Bel, E.2
Thomas, M.3
|